Exact Mass: 315.2409

Exact Mass Matches: 315.2409

Found 258 metabolites which its exact mass value is equals to given mass value 315.2409, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Decanoylcarnitine (C10)

(3R)-3-(decanoyloxy)-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


Decanoylcarnitine is a member of the class of compounds known as acylcarnitines. More specifically, it is a decanoic acid ester of carnitine. Acylcarnitines were first discovered in the 1940s (PMID: 13825279 ). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Decanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine decanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494 ). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular decanoylcarnitine is elevated in the blood or plasma of individuals with obesity in adolescence (PMID: 26910390 ). It is also decreased in the blood or plasma of individuals with adolescent idiopathic scoliosis (PMID: 26928931 ). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279 ). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. Acylcarnitine useful in the diagnosis of fatty acid oxidation disorders and differentiation between biochemical phenotypes of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency deficiencyoxidation disorders.(PMID: 12385891) [HMDB]

   

CID 5281853

CID 5281853

C20H33N3 (315.2674)


   

Bremazocine

Bremazocine

C20H29NO2 (315.2198)


D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Butoctamide

Butoctamide hydrogen succinate

C16H29NO5 (315.2046)


Same as: D01498

   

Dehydrophytosphingosine

Dehydrophytosphingosine (not validated, isomer of 1677)

C18H37NO3 (315.2773)


Dehydrophytosphingosine is found in pulses. Dehydrophytosphingosine is present in soybean phospholipids. Present in soybean phospholipids. Dehydrophytosphingosine is found in pulses.

   

(±)-Pandamarine

3-methyl-6-{4-[(2E)-4-methyl-5-oxo-2,5-dihydro-1H-pyrrol-2-ylidene]butyl}-1,6-diazaspiro[4.5]dec-3-en-2-one

C18H25N3O2 (315.1947)


(±)-Pandamarine is a major alkaloid from leaves of Pandanus amaryllifolius. Major alkaloid from leaves of Pandanus amaryllifolius

   

Val-Val-Val

2-({2-[(2-amino-1-hydroxy-3-methylbutylidene)amino]-1-hydroxy-3-methylbutylidene}amino)-3-methylbutanoate

C15H29N3O4 (315.2158)


Val-val-val is classified as a member of the oligopeptides. Oligopeptides are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds. Val-val-val is considered to be a slightly soluble (in water) and a weak acidic compound. Val-val-val can be found in feces.

   

Saxagliptin

(1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile

C18H25N3O2 (315.1947)


Saxagliptin (rINN), previously identified as BMS-477118, is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. It was developed by Bristol-Myers Squibb. A New Drug Application for saxagliptin in the treatment of type 2 diabetes was submitted to the FDA in June 2008. It was based on a drug development program with 8 randomized trials: 1 phase 2 dose-ranging (2.5 - 100 mg/d) study; 6 phase 3, 24-week controlled trials with additional controlled follow-up from 12 to 42 months, double-blinded throughout; and one 12-week mechanism-of-action trial with a 2-year follow-up period. In June 2008, it was announced that Onglyza would be the trade name under which saxagliptin will be marketed. A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

   

6-Methylnonanoylcarnitine

3-[(6-methylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


6-Methylnonanoylcarnitine is an acylcarnitine. More specifically, it is an 6-methylnonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Methylnonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Methylnonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Methylnonanoylcarnitine

3-[(5-methylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


5-Methylnonanoylcarnitine is an acylcarnitine. More specifically, it is an 5-methylnonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Methylnonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Methylnonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-Methylnonanoylcarnitine

3-[(8-methylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


8-Methylnonanoylcarnitine is an acylcarnitine. More specifically, it is an 8-methylnonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Methylnonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 8-Methylnonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Methylnonanoylcarnitine

3-[(7-methylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


7-Methylnonanoylcarnitine is an acylcarnitine. More specifically, it is an 7-methylnonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Methylnonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Methylnonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Methylnonanoylcarnitine

3-[(4-methylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


4-Methylnonanoylcarnitine is an acylcarnitine. More specifically, it is an 4-methylnonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Methylnonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Methylnonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Methylnonanoylcarnitine

3-[(3-methylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


3-Methylnonanoylcarnitine is an acylcarnitine. More specifically, it is an 3-methylnonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Methylnonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Methylnonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2Z)-6-Hydroxynon-2-enoylcarnitine

3-[(6-Hydroxynon-2-enoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H29NO5 (315.2046)


(2Z)-6-hydroxynon-2-enoylcarnitine is an acylcarnitine. More specifically, it is an (2Z)-6-hydroxynon-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z)-6-hydroxynon-2-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2Z)-6-hydroxynon-2-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxynon-7-enoylcarnitine

3-[(6-hydroxynon-7-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


6-hydroxynon-7-enoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxynon-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-hydroxynon-7-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-hydroxynon-7-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxynon-3-enoylcarnitine

3-[(6-Hydroxynon-3-enoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H29NO5 (315.2046)


6-hydroxynon-3-enoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxynon-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-hydroxynon-3-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-hydroxynon-3-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxynon-4-enoylcarnitine

3-[(6-hydroxynon-4-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


6-hydroxynon-4-enoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxynon-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-hydroxynon-4-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-hydroxynon-4-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxynon-5-enoylcarnitine

3-[(6-hydroxynon-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


6-hydroxynon-5-enoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxynon-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-hydroxynon-5-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-hydroxynon-5-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxynon-6-enoylcarnitine

3-[(6-hydroxynon-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


6-hydroxynon-6-enoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxynon-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-hydroxynon-6-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-hydroxynon-6-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Oxononanoylcarnitine

3-[(7-oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


7-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 7-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Oxononanoylcarnitine

3-[(5-Oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H29NO5 (315.2046)


5-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 5-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-Oxononanoylcarnitine

3-[(8-oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


8-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 8-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 8-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Oxononanoylcarnitine

3-[(3-Oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H29NO5 (315.2046)


3-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 3-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Oxononanoylcarnitine

3-[(6-Oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H29NO5 (315.2046)


6-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 6-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Oxononanoylcarnitine

3-[(4-oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


4-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 4-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-Oxononanoylcarnitine

3-[(9-oxononanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H29NO5 (315.2046)


9-Oxononanoylcarnitine is an acylcarnitine. More specifically, it is an 9-oxononanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Oxononanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 9-Oxononanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Lauroyl Aspartic acid

2-(Dodecanoylamino)butanedioic acid

C16H29NO5 (315.2046)


N-lauroyl aspartic acid, also known as N-lauroyl aspartate belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Lauric acid amide of Aspartic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Lauroyl Aspartic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Lauroyl Aspartic acid is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Myristoyl Serine

3-hydroxy-2-tetradecanamidopropanoic acid

C17H33NO4 (315.2409)


N-myristoyl serine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Myristic acid amide of Serine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Myristoyl Serine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Myristoyl Serine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

(-)-Bremazocine

1-ethyl-10-[(1-hydroxycyclopropyl)methyl]-13,13-dimethyl-10-azatricyclo[7.3.1.0^{2,7}]trideca-2(7),3,5-trien-4-ol

C20H29NO2 (315.2198)


   

Fendiline

Celltech brand OF fendiline hydrochloride

C23H25N (315.1987)


C - Cardiovascular system > C08 - Calcium channel blockers > C08E - Non-selective calcium channel blockers > C08EA - Phenylalkylamine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

Pamaquine

8-((4-(Diethylamino)-1-methylbutyl)amino)-6-methoxyquinoline

C19H29N3O (315.2311)


   

(R)-N1-((S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide

2-[(Dihydroxycarbonimidoyl)methyl]-N-[2,2-dimethyl-1-(methyl-C-hydroxycarbonimidoyl)propyl]-4-methylpentanimidate

C15H29N3O4 (315.2158)


   

Piperidine, 1-(4-(1-methyl-1-(4-methylcyclohexyl)ethoxy)phenyl)-, cis-

Piperidine, 1-(4-(1-methyl-1-(4-methylcyclohexyl)ethoxy)phenyl)-, cis-

C21H33NO (315.2562)


   

(9R,10S)-dihydroxystearate

9,10-Dihydroxyoctadecanoic acid

C18H35O4- (315.2535)


(9r,10s)-dihydroxystearate, also known as 9,10-dihydroxyoctadecanoate, is a member of the class of compounds known as long-chain fatty acids. Long-chain fatty acids are fatty acids with an aliphatic tail that contains between 13 and 21 carbon atoms (9r,10s)-dihydroxystearate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). (9r,10s)-dihydroxystearate can be found in a number of food items such as pulses, sorghum, yautia, and european plum, which makes (9r,10s)-dihydroxystearate a potential biomarker for the consumption of these food products.

   

gibberellin A12-aldehyde

(1R,2S,3S,4R,8S,9S,12R)-2-formyl-4,8-dimethyl-13-methylidenetetracyclo[10.2.1.0¹,⁹.0³,⁸]pentadecane-4-carboxylate

C20H27O3 (315.196)


Gibberellin a12-aldehyde is a member of the class of compounds known as c20-gibberellins. C20-gibberellins are gibberellins with carboxy groups in positions 7 and 18 and some also in 20, while others have an aldehyde group in the latter position. Gibberellin a12-aldehyde is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Gibberellin a12-aldehyde can be found in a number of food items such as custard apple, yellow bell pepper, giant butterbur, and java plum, which makes gibberellin a12-aldehyde a potential biomarker for the consumption of these food products.

   

SCHEMBL18891611

SCHEMBL18891611

C21H33NO (315.2562)


   

N-Formyl-7-amino-11-cycloamphilectene

N-Formyl-7-amino-11-cycloamphilectene

C21H33NO (315.2562)


   

3-(2-heptylcyclopropyl)-N-phenylethylpropanamide

3-(2-heptylcyclopropyl)-N-phenylethylpropanamide

C21H33NO (315.2562)


   

17β-Hydroxy-androstano[3,2-c]isoxazole

17β-Hydroxy-androstano[3,2-c]isoxazole

C20H29NO2 (315.2198)


   

N-(4-Hydroxyphenethyl)-2,4-dodecadienamid

N-(4-Hydroxyphenethyl)-2,4-dodecadienamid

C20H29NO2 (315.2198)


   

Alkaloid GB13

Alkaloid GB13

C20H29NO2 (315.2198)


   
   

(1S*,3S*,4R*,7S*,8S*,12S*,13S*)-7-formamidocycloamphilect-11(20)-ene

(1S*,3S*,4R*,7S*,8S*,12S*,13S*)-7-formamidocycloamphilect-11(20)-ene

C21H33NO (315.2562)


   

podopetaline monohydrochloride

podopetaline monohydrochloride

C20H33N3 (315.2674)


   

(E,E)-N-(4-Hydroxyphenethyl)-2,4-dodecadienamide

(E,E)-N-(4-Hydroxyphenethyl)-2,4-dodecadienamide

C20H29NO2 (315.2198)


   

11,12-didehydro-ormosanine|Panamin

11,12-didehydro-ormosanine|Panamin

C20H33N3 (315.2674)


   
   

caldaphnidine G

caldaphnidine G

C21H33NO (315.2562)


   

(1R*,3S*,4R*,7S*,8S*,12S*,13S*)-7-formamidoamphilecta-11(20),14-diene

(1R*,3S*,4R*,7S*,8S*,12S*,13S*)-7-formamidoamphilecta-11(20),14-diene

C21H33NO (315.2562)


   

10-Epimartensine A|Martensine A

10-Epimartensine A|Martensine A

C18H25N3O2 (315.1947)


   

cavernene B

cavernene B

C21H33NO (315.2562)


   

(1(14)-E,3S,4R,7S,8S,11R,12S,13R)-7-formamidoisoneoamphilecta-1(14),15-diene|7-formamidoisoneoamphilecta-1(14),15-diene

(1(14)-E,3S,4R,7S,8S,11R,12S,13R)-7-formamidoisoneoamphilecta-1(14),15-diene|7-formamidoisoneoamphilecta-1(14),15-diene

C21H33NO (315.2562)


   

Leptophyllin A

Leptophyllin A

C18H37NO3 (315.2773)


   

(1S*,3S*,4R*,7S*,8S*,12S*,13S*)-7-formamidoamphilecta-11(20),15-diene

(1S*,3S*,4R*,7S*,8S*,12S*,13S*)-7-formamidoamphilecta-11(20),15-diene

C21H33NO (315.2562)


   

inakt.Leucyl-glycyl-leucin-methylester|Leucyl=>glycyl=>leucin-methylester|leucyl=>glycyl=>leucine methyl ester

inakt.Leucyl-glycyl-leucin-methylester|Leucyl=>glycyl=>leucin-methylester|leucyl=>glycyl=>leucine methyl ester

C15H29N3O4 (315.2158)


   

(-)-indolactam I|(-)-indolactam-Ile|Indolactam I

(-)-indolactam I|(-)-indolactam-Ile|Indolactam I

C18H25N3O2 (315.1947)


   
   
   
   
   
   
   

fendiline

fendiline

C23H25N (315.1987)


C - Cardiovascular system > C08 - Calcium channel blockers > C08E - Non-selective calcium channel blockers > C08EA - Phenylalkylamine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   
   
   
   
   
   
   
   

Saxagliptin (BMS-477118,Onglyza)

"Saxagliptin (BMS-477118,Onglyza)"

C18H25N3O2 (315.1947)


   

(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide

NCGC00380344-01!(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide

C20H29NO2 (315.2198)


   

Decanoylcarnitine

Decanoylcarnitine

C17H33NO4 (315.2409)


   

(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide

(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide

C20H29NO2 (315.2198)


   

Decanoyl-L-carnitine

Decanoyl-L-carnitine

C17H33NO4 (315.2409)


CONFIDENCE standard compound; INTERNAL_ID 249

   

C13DEA

N,N-Bis(2-hydroxyethyl)tetradecanamide

C18H37NO3 (315.2773)


Literature spectrum; CONFIDENCE Tentative identification: isomers possible (Level 3); May be an alkyl homologue; Digitised from figure: approximate intensities

   

Dehydrophytosphingosine (not validated, isomer of 1677)

Dehydrophytosphingosine (not validated, isomer of 1677)

C18H37NO3 (315.2773)


Annotation level-3

   

Dehydrophytosphingosine (not validated, isomer of 1679)

Dehydrophytosphingosine (not validated, isomer of 1679)

C18H37NO3 (315.2773)


Annotation level-3

   

(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide [IIN-based on: CCMSLIB00000846683]

NCGC00380344-01!(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide [IIN-based on: CCMSLIB00000846683]

C20H29NO2 (315.2198)


   

(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide [IIN-based: Match]

NCGC00380344-01!(2E,4E)-N-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienamide [IIN-based: Match]

C20H29NO2 (315.2198)


   

Decanoyl-carnitine; AIF; CE0; CorrDec

Decanoyl-carnitine; AIF; CE0; CorrDec

C17H33NO4 (315.2409)


   

Decanoyl-carnitine; AIF; CE10; CorrDec

Decanoyl-carnitine; AIF; CE10; CorrDec

C17H33NO4 (315.2409)


   

Decanoyl-carnitine; AIF; CE30; CorrDec

Decanoyl-carnitine; AIF; CE30; CorrDec

C17H33NO4 (315.2409)


   

Decanoyl-carnitine; AIF; CE0; MS2Dec

Decanoyl-carnitine; AIF; CE0; MS2Dec

C17H33NO4 (315.2409)


   

Decanoyl-carnitine; AIF; CE10; MS2Dec

Decanoyl-carnitine; AIF; CE10; MS2Dec

C17H33NO4 (315.2409)


   

Decanoyl-carnitine; AIF; CE30; MS2Dec

Decanoyl-carnitine; AIF; CE30; MS2Dec

C17H33NO4 (315.2409)


   
   
   
   
   
   
   
   
   
   
   

L-Hexanoylcarnitine n-butyl ester

L-Hexanoylcarnitine n-butyl ester

C17H33NO4 (315.2409)


   

Dehydrophytosphingosine

4R-hydroxysphing-8E-enine

C18H37NO3 (315.2773)


   

6-hydroxysphingosine

6-hydroxysphing-4E-enine

C18H37NO3 (315.2773)


   

4R-hydroxy-sphing-8Z-enine

4R-hydroxy-sphing-8Z-enine

C18H37NO3 (315.2773)


   

saxagliptin

(1S,3S,5S)-2-[(2S)-2-amino-2-[(1r,3R,5R,7S)-3-hydroxyadamantan-1-yl]acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

C18H25N3O2 (315.1947)


A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

   

(±)-Pandamarine

3-methyl-6-{4-[(2E)-4-methyl-5-oxo-2,5-dihydro-1H-pyrrol-2-ylidene]butyl}-1,6-diazaspiro[4.5]dec-3-en-2-one

C18H25N3O2 (315.1947)


   

(2E,4E)-N-[2-(4-Hydroxyphenyl)ethyl]-2,4-dodecadienamide

(2E,4E)-N-[2-(4-Hydroxyphenyl)ethyl]-2,4-dodecadienamide

C20H29NO2 (315.2198)


   

CAR 10:0

3-(decanoyloxy)-4-(trimethylazaniumyl)butanoate

C17H33NO4 (315.2409)


   

NA 20:6;O

Dodeca-2E,4E-dienoic acid 4-hydroxy-2-phenylethylamide

C20H29NO2 (315.2198)


   

SPB 18:1;O3

4R-hydroxy-sphing-8Z-enine

C18H37NO3 (315.2773)


   

N,N-bis(2-hydroxypropyl)dodecanamide

N,N-bis(2-hydroxypropyl)dodecanamide

C18H37NO3 (315.2773)


   

4-Piperidinecarboxamide,4-(cyclohexylamino)-1-(phenylmethyl)-

4-Piperidinecarboxamide,4-(cyclohexylamino)-1-(phenylmethyl)-

C19H29N3O (315.2311)


   

1-(Pyrrolidin-1-yl)-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanone

1-(Pyrrolidin-1-yl)-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanone

C18H26BNO3 (315.2006)


   

4-(Piperidine-1-carbonyl)phenylboronic acid pinacol ester

4-(Piperidine-1-carbonyl)phenylboronic acid pinacol ester

C18H26BNO3 (315.2006)


   

TERT-BUTYL 5-(4-METHYLPIPERAZIN-1-YL)-1H-INDOLE-1-CARBOXYLATE

TERT-BUTYL 5-(4-METHYLPIPERAZIN-1-YL)-1H-INDOLE-1-CARBOXYLATE

C18H25N3O2 (315.1947)


   

N-Myristoyl-L-serine

N-Myristoyl-L-serine

C17H33NO4 (315.2409)


   

(R)-3-Cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile

(R)-3-Cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile

C17H26BN3O2 (315.2118)


   

3-ACETYL-N-TRIISOPROPYLSILYL INDOLE

3-ACETYL-N-TRIISOPROPYLSILYL INDOLE

C19H29NOSi (315.2018)


   

Lauroyliminodiacetic acid

Lauroyliminodiacetic acid

C16H29NO5 (315.2046)


   

(S)-3-(1-Boc-2-piperazinylmethyl)indole

(S)-3-(1-Boc-2-piperazinylmethyl)indole

C18H25N3O2 (315.1947)


   

Boc-12-Ado-OH

Boc-12-Ado-OH

C17H33NO4 (315.2409)


   

(1R,3R,5R)-2-[(2R)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

(1R,3R,5R)-2-[(2R)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

C18H25N3O2 (315.1947)


   

Saxagliptin (S,R,S,S)-Isomer

Saxagliptin (S,R,S,S)-Isomer

C18H25N3O2 (315.1947)


   

Saxagliptin (R,S,R,S)-Isomer

Saxagliptin (R,S,R,S)-Isomer

C18H25N3O2 (315.1947)


   
   

3-(2-phenyl-2-Cyclopentyl-2-hydroxyethoxy)quinuclidine

3-(2-phenyl-2-Cyclopentyl-2-hydroxyethoxy)quinuclidine

C20H29NO2 (315.2198)


   

2-[(3-benzyl-4,7,7-trimethyl-3-bicyclo[2.2.1]heptanyl)oxy]-N,N-dimethylethanamine

2-[(3-benzyl-4,7,7-trimethyl-3-bicyclo[2.2.1]heptanyl)oxy]-N,N-dimethylethanamine

C21H33NO (315.2562)


   

3-(Piperidine-1-carbonyl)phenylboronic acid, pinacol ester

3-(Piperidine-1-carbonyl)phenylboronic acid, pinacol ester

C18H26BNO3 (315.2006)


   

pamaquine

pamaquine

C19H29N3O (315.2311)


C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent

   

2-[[2-[(2-Amino-3-methylbutanoyl)amino]-3-methylbutanoyl]amino]-3-methylbutanoic acid

2-[[2-[(2-Amino-3-methylbutanoyl)amino]-3-methylbutanoyl]amino]-3-methylbutanoic acid

C15H29N3O4 (315.2158)


   

H-Val-Val-Val-OH

H-Val-Val-Val-OH

C15H29N3O4 (315.2158)


   

Leu-Leu-Ala

Leu-Leu-Ala

C15H29N3O4 (315.2158)


A tripeptide composed of two L-leucine units joined to L-alanine by a peptide linkage.

   

17beta-Hydroxy-androstano[3,2-c]isoxazole

17beta-Hydroxy-androstano[3,2-c]isoxazole

C20H29NO2 (315.2198)


   

(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid

(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid

C15H29N3O4 (315.2158)


   

L-Alanine, L-isoleucyl-L-isoleucyl-

L-Alanine, L-isoleucyl-L-isoleucyl-

C15H29N3O4 (315.2158)


   

2-Butoxy-N-[2-(dimethylamino)ethyl]quinoline-4-carboxamide

2-Butoxy-N-[2-(dimethylamino)ethyl]quinoline-4-carboxamide

C18H25N3O2 (315.1947)


   

N-Dodecylphthalimide

N-Dodecylphthalimide

C20H29NO2 (315.2198)


   

(R)-N1-((S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-2-isobutylsuccinamide

2-[(Dihydroxycarbonimidoyl)methyl]-N-[2,2-dimethyl-1-(methyl-C-hydroxycarbonimidoyl)propyl]-4-methylpentanimidate

C15H29N3O4 (315.2158)


   

gibberellin A12 aldehyde(1-)

gibberellin A12 aldehyde(1-)

C20H27O3- (315.196)


   

(9S,10S)-9,10-dihydroxyoctadecanoate

(9S,10S)-9,10-dihydroxyoctadecanoate

C18H35O4- (315.2535)


Conjugate base of (9S,10S)-9,10-dihydroxyoctadecanoic acid.

   

N-(3-oxododecanoyl)-L-homoserine

N-(3-oxododecanoyl)-L-homoserine

C16H29NO5 (315.2046)


   

15-deoxy-Delta(12,14)-prostaglandin J2(1-)

15-deoxy-Delta(12,14)-prostaglandin J2(1-)

C20H27O3- (315.196)


A prostaglandin carboxylic acid anion that is the conjugate base of 15-deoxy-Delta(12,14)-prostaglandin J2. obtained by deprotonation of the carboxy group; major species at pH 7.3. D007155 - Immunologic Factors

   

kauralexin B3

kauralexin B3

C20H27O3- (315.196)


   
   

(9R,10S)-dihydroxystearate

(9R,10S)-dihydroxystearate

C18H35O4- (315.2535)


   

(2S,3S,4R)-2-aminooctadec-8-ene-1,3,4-triol

(2S,3S,4R)-2-aminooctadec-8-ene-1,3,4-triol

C18H37NO3 (315.2773)


   

(2S,3R,6R)-2-Amino-4-octadecene-1,3,6-triol

(2S,3R,6R)-2-Amino-4-octadecene-1,3,6-triol

C18H37NO3 (315.2773)


   

(3aS,6R,7aS)-6-ethyl-N-[(2S)-2-ethyl-1-prop-1-en-2-ylcyclopropyl]-1-oxo-2,3,3a,6,7,7a-hexahydroindene-4-carboxamide

(3aS,6R,7aS)-6-ethyl-N-[(2S)-2-ethyl-1-prop-1-en-2-ylcyclopropyl]-1-oxo-2,3,3a,6,7,7a-hexahydroindene-4-carboxamide

C20H29NO2 (315.2198)


   

7-Oxononanoylcarnitine

7-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

5-Oxononanoylcarnitine

5-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

8-Oxononanoylcarnitine

8-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

3-Oxononanoylcarnitine

3-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

6-Oxononanoylcarnitine

6-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

4-Oxononanoylcarnitine

4-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

9-Oxononanoylcarnitine

9-Oxononanoylcarnitine

C16H29NO5 (315.2046)


   

6-Methylnonanoylcarnitine

6-Methylnonanoylcarnitine

C17H33NO4 (315.2409)


   

5-Methylnonanoylcarnitine

5-Methylnonanoylcarnitine

C17H33NO4 (315.2409)


   

8-Methylnonanoylcarnitine

8-Methylnonanoylcarnitine

C17H33NO4 (315.2409)


   

7-Methylnonanoylcarnitine

7-Methylnonanoylcarnitine

C17H33NO4 (315.2409)


   

4-Methylnonanoylcarnitine

4-Methylnonanoylcarnitine

C17H33NO4 (315.2409)


   

3-Methylnonanoylcarnitine

3-Methylnonanoylcarnitine

C17H33NO4 (315.2409)


   

6-Hydroxynon-7-enoylcarnitine

6-Hydroxynon-7-enoylcarnitine

C16H29NO5 (315.2046)


   

6-Hydroxynon-3-enoylcarnitine

6-Hydroxynon-3-enoylcarnitine

C16H29NO5 (315.2046)


   

6-Hydroxynon-4-enoylcarnitine

6-Hydroxynon-4-enoylcarnitine

C16H29NO5 (315.2046)


   

6-Hydroxynon-5-enoylcarnitine

6-Hydroxynon-5-enoylcarnitine

C16H29NO5 (315.2046)


   

6-Hydroxynon-6-enoylcarnitine

6-Hydroxynon-6-enoylcarnitine

C16H29NO5 (315.2046)


   

(2Z)-6-Hydroxynon-2-enoylcarnitine

(2Z)-6-Hydroxynon-2-enoylcarnitine

C16H29NO5 (315.2046)


   
   

N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine

N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine

C17H25N5O (315.2059)


   

Halisphingosine A

Halisphingosine A

C18H37NO3 (315.2773)


A sphingoid that is octadec-7-ene substituted by an amino group at position 2 and hydroxy groups at positions 1, 3 and 6 (the 2R,3R,6R,7Z stereoisomer). It is isolated from the marine sponge Haliclona.

   

3,18-Dihydroxystearate

3,18-Dihydroxystearate

C18H35O4- (315.2535)


An omega-hydroxy fatty acid anion that is the conjugate base of 3,18-dihydroxystearic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

12,18-Dihydroxyoctadecanoate

12,18-Dihydroxyoctadecanoate

C18H35O4- (315.2535)


A hydroxy fatty acid anion that is the conjugate base of 12,18-dihydroxyoctadecanoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(5S)-1-heptyl-5-(2-methylpropyl)-N-phenyl-4,5-dihydroimidazol-2-amine

(5S)-1-heptyl-5-(2-methylpropyl)-N-phenyl-4,5-dihydroimidazol-2-amine

C20H33N3 (315.2674)


   

all-trans-(4S)-hydroxyretinoate

all-trans-(4S)-hydroxyretinoate

C20H27O3- (315.196)


   

all-trans-4-Hydroxyretinoate

all-trans-4-Hydroxyretinoate

C20H27O3- (315.196)


A hydroxy monocarboxylic acid anion that is the conjugate base of all-trans-4-hydroxyretinoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

all-trans-18-Hydroxyretinoate

all-trans-18-Hydroxyretinoate

C20H27O3- (315.196)


A retinoid anion that is the conjugate base of all-trans-18-hydroxyretinoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(2E,4E,6E,8E)-3,7-dimethyl-9-(2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)nona-2,4,6,8-tetraenoate

(2E,4E,6E,8E)-3,7-dimethyl-9-(2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)nona-2,4,6,8-tetraenoate

C20H27O3- (315.196)


   

(9R,10R)-9,10-dihydroxyoctadecanoate

(9R,10R)-9,10-dihydroxyoctadecanoate

C18H35O4- (315.2535)


   

(2R)-2-hydroperoxyoctadecanoate

(2R)-2-hydroperoxyoctadecanoate

C18H35O4- (315.2535)


   
   
   
   
   
   

Alanine, N-methyl-N-methoxycarbonyl-, undecyl ester

Alanine, N-methyl-N-methoxycarbonyl-, undecyl ester

C17H33NO4 (315.2409)


   
   
   
   
   

(9S,10R)-dihydroxyoctadecanoate

(9S,10R)-dihydroxyoctadecanoate

C18H35O4- (315.2535)


A hydroxy fatty acid anion that is the conjugate base of (9S,10R)-dihydroxyoctadecanoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

Ectocarpin B

Ectocarpin B

C20H27O3- (315.196)


   
   

All-trans-16-hydroxyretinoate

All-trans-16-hydroxyretinoate

C20H27O3- (315.196)


   

5-Oxoeicosapentaenoate

5-Oxoeicosapentaenoate

C20H27O3- (315.196)


   

9-cis-4-Hydroxyretinoate

9-cis-4-Hydroxyretinoate

C20H27O3- (315.196)


   

10,13-Dihydroxyoctadecanoate

10,13-Dihydroxyoctadecanoate

C18H35O4- (315.2535)


   

(3R)-3-decanoyloxy-4-[dimethyl(trideuteriomethyl)azaniumyl]butanoate

(3R)-3-decanoyloxy-4-[dimethyl(trideuteriomethyl)azaniumyl]butanoate

C17H33NO4 (315.2409)


   

4-Oxo-all-trans-13,14-dihydroretinoate

4-Oxo-all-trans-13,14-dihydroretinoate

C20H27O3- (315.196)


   

Saxagliptin (BMS-477118,Onglyza)

Saxagliptin (BMS-477118,Onglyza)

C18H25N3O2 (315.1947)


A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors

   

2-Ethoxy-N-(2-(diethylamino)ethyl)-4-quinolinecarboxamide

2-Ethoxy-N-(2-(diethylamino)ethyl)-4-quinolinecarboxamide

C18H25N3O2 (315.1947)


   

N-(1,3-dihydroxyhexadecan-2-yl)acetamide

N-(1,3-dihydroxyhexadecan-2-yl)acetamide

C18H37NO3 (315.2773)


   

2-Butoxy-N-(2-(ethylamino)ethyl)-4-quinolinecarboxamide

2-Butoxy-N-(2-(ethylamino)ethyl)-4-quinolinecarboxamide

C18H25N3O2 (315.1947)


   

N-(1,3-dihydroxynonan-2-yl)nonanamide

N-(1,3-dihydroxynonan-2-yl)nonanamide

C18H37NO3 (315.2773)


   

N-(1,3-dihydroxydodecan-2-yl)hexanamide

N-(1,3-dihydroxydodecan-2-yl)hexanamide

C18H37NO3 (315.2773)


   

N-(1,3-dihydroxydecan-2-yl)octanamide

N-(1,3-dihydroxydecan-2-yl)octanamide

C18H37NO3 (315.2773)


   

N-(1,3-dihydroxytetradecan-2-yl)butanamide

N-(1,3-dihydroxytetradecan-2-yl)butanamide

C18H37NO3 (315.2773)


   

N-(1,3-dihydroxypentadecan-2-yl)propanamide

N-(1,3-dihydroxypentadecan-2-yl)propanamide

C18H37NO3 (315.2773)


   

N-(1,3-dihydroxyoctan-2-yl)decanamide

N-(1,3-dihydroxyoctan-2-yl)decanamide

C18H37NO3 (315.2773)


   

N-(1,3-dihydroxytridecan-2-yl)pentanamide

N-(1,3-dihydroxytridecan-2-yl)pentanamide

C18H37NO3 (315.2773)


   

N-(1,3-dihydroxyundecan-2-yl)heptanamide

N-(1,3-dihydroxyundecan-2-yl)heptanamide

C18H37NO3 (315.2773)


   

O-Decanoyl-L-carnitine

O-Decanoyl-L-carnitine

C17H33NO4 (315.2409)


An O-acyl-L-carnitine that is L-carnitine having decanoyl as the acyl substituent.

   

CID 5281853

CID 5281853

C20H33N3 (315.2674)


   

4-hydroxy-8cis-sphingenine

4-hydroxy-8cis-sphingenine

C18H37NO3 (315.2773)


   

(+)-pisiferate

(+)-pisiferate

C20H27O3 (315.196)


A monocarboxylic acid anion that is the conjugate base of (+)-pisiferic acid, arising from the deprotonation of the carboxy group. Major species at pH 7.3.

   

9,10-Dihydroxystearate

9,10-Dihydroxystearate

C18H35O4- (315.2535)


A long-chain fatty acid anion that is the conjugate base of 9,10-dihydroxystearic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

O-decanoylcarnitine

O-decanoylcarnitine

C17H33NO4 (315.2409)


An O-acylcarnitine compound having decanoyl as the acyl substituent.

   

6-hydroxysphing-4E-enine

6-hydroxysphing-4E-enine

C18H37NO3 (315.2773)


A sphingoid that is sphingosine with an additional hydroxy group at position 6

   

(S)-all-trans-4-hydroxyretinoate

(S)-all-trans-4-hydroxyretinoate

C20H27O3 (315.196)


An all-trans-4-hydroxyretinoate that is the conjugate base of (S)-all-trans-4-hydroxyretinoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

5,6-epoxyretinoate

5,6-epoxyretinoate

C20H27O3 (315.196)


A monocarboxylic acid anion that is the conjugate base of 5,6-epoxyretinoic acid arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   
   
   
   
   
   
   
   
   
   
   

Hydroxysphingosine

Hydroxysphingosine

C18H37NO3 (315.2773)


   

2-{5-[(2e)-5-[(1r)-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-en-1-yl]-3h-imidazol-4-yl}ethanamine

2-{5-[(2e)-5-[(1r)-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-en-1-yl]-3h-imidazol-4-yl}ethanamine

C20H33N3 (315.2674)


   

(1r,11s,13r,14r)-7,19,23-triazahexacyclo[9.9.1.1¹,¹³.1²,⁶.0⁷,²¹.0¹⁴,¹⁹]tricosane

(1r,11s,13r,14r)-7,19,23-triazahexacyclo[9.9.1.1¹,¹³.1²,⁶.0⁷,²¹.0¹⁴,¹⁹]tricosane

C20H33N3 (315.2674)


   

3,17,17-trimethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16),14-triene-5,14-diol

3,17,17-trimethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16),14-triene-5,14-diol

C20H29NO2 (315.2198)


   

(10s,13s)-10-[(2s)-butan-2-yl]-13-(hydroxymethyl)-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

(10s,13s)-10-[(2s)-butan-2-yl]-13-(hydroxymethyl)-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C18H25N3O2 (315.1947)


   

1-[(1s,3as,3bs,7r,9ar,9bs,11as)-7-amino-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

1-[(1s,3as,3bs,7r,9ar,9bs,11as)-7-amino-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C21H33NO (315.2562)


   

1-[(1r,3ar,3br,7r,9as,9br,11as)-7-amino-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

1-[(1r,3ar,3br,7r,9as,9br,11as)-7-amino-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C21H33NO (315.2562)


   

(1r,2s,6s,11r,13s,14s,21s)-7,19,23-triazahexacyclo[9.9.1.1¹,¹³.1²,⁶.0⁷,²¹.0¹⁴,¹⁹]tricosane

(1r,2s,6s,11r,13s,14s,21s)-7,19,23-triazahexacyclo[9.9.1.1¹,¹³.1²,⁶.0⁷,²¹.0¹⁴,¹⁹]tricosane

C20H33N3 (315.2674)


   

13-(hydroxymethyl)-9-methyl-10-(sec-butyl)-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

13-(hydroxymethyl)-9-methyl-10-(sec-butyl)-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C18H25N3O2 (315.1947)


   

(2s)-12-[(2r,5s,6s)-5-hydroxy-6-methylpiperidin-2-yl]dodecane-1,2-diol

(2s)-12-[(2r,5s,6s)-5-hydroxy-6-methylpiperidin-2-yl]dodecane-1,2-diol

C18H37NO3 (315.2773)


   

1-(piperidin-2-yl)-3,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadec-2-ene

1-(piperidin-2-yl)-3,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadec-2-ene

C20H33N3 (315.2674)


   

12-[(2r,5s,6s)-5-hydroxy-6-methylpiperidin-2-yl]dodecane-1,2-diol

12-[(2r,5s,6s)-5-hydroxy-6-methylpiperidin-2-yl]dodecane-1,2-diol

C18H37NO3 (315.2773)


   

(1r,7as)-1-({[2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoyl]oxy}methyl)-hexahydro-1h-pyrrolizin-4-ium-4-olate

(1r,7as)-1-({[2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoyl]oxy}methyl)-hexahydro-1h-pyrrolizin-4-ium-4-olate

C16H29NO5 (315.2046)


   

{3-ethyl-16-methyl-1-azapentacyclo[9.6.1.0²,¹⁵.0³,¹².0⁴,⁸]octadec-4-en-12-yl}methanol

{3-ethyl-16-methyl-1-azapentacyclo[9.6.1.0²,¹⁵.0³,¹².0⁴,⁸]octadec-4-en-12-yl}methanol

C21H33NO (315.2562)


   

1-(piperidin-2-yl)-3,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadec-7-ene

1-(piperidin-2-yl)-3,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadec-7-ene

C20H33N3 (315.2674)


   

n-[(1s,3ar,3a¹r,4s,5as,10ar)-1,4,7,7-tetramethyl-2,3,3a,3a¹,4,5,5a,6,8,9,10,10a-dodecahydropyren-1-yl]carboximidic acid

n-[(1s,3ar,3a¹r,4s,5as,10ar)-1,4,7,7-tetramethyl-2,3,3a,3a¹,4,5,5a,6,8,9,10,10a-dodecahydropyren-1-yl]carboximidic acid

C21H33NO (315.2562)


   

[(2r,3r,8s,11s,12r,15r,16s)-3-ethyl-16-methyl-1-azapentacyclo[9.6.1.0²,¹⁵.0³,¹².0⁴,⁸]octadec-4-en-12-yl]methanol

[(2r,3r,8s,11s,12r,15r,16s)-3-ethyl-16-methyl-1-azapentacyclo[9.6.1.0²,¹⁵.0³,¹².0⁴,⁸]octadec-4-en-12-yl]methanol

C21H33NO (315.2562)


   

3-(2-heptylcyclopropyl)-n-(2-phenylethyl)propanimidic acid

3-(2-heptylcyclopropyl)-n-(2-phenylethyl)propanimidic acid

C21H33NO (315.2562)


   

(2e,4e)-n-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienimidic acid

(2e,4e)-n-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienimidic acid

C20H29NO2 (315.2198)


   

(1r,3e,5s,10r)-3,17,17-trimethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16),14-triene-5,14-diol

(1r,3e,5s,10r)-3,17,17-trimethyl-7-methylidene-15-azatricyclo[8.5.2.0¹³,¹⁶]heptadeca-3,13(16),14-triene-5,14-diol

C20H29NO2 (315.2198)


   

n-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienimidic acid

n-[2-(4-hydroxyphenyl)ethyl]dodeca-2,4-dienimidic acid

C20H29NO2 (315.2198)


   

12-(5-hydroxy-6-methylpiperidin-2-yl)dodecane-1,2-diol

12-(5-hydroxy-6-methylpiperidin-2-yl)dodecane-1,2-diol

C18H37NO3 (315.2773)


   

1-{7-amino-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethanone

1-{7-amino-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethanone

C21H33NO (315.2562)


   

7,19,23-triazahexacyclo[9.9.1.1¹,¹³.1²,⁶.0⁷,²¹.0¹⁴,¹⁹]tricosane

7,19,23-triazahexacyclo[9.9.1.1¹,¹³.1²,⁶.0⁷,²¹.0¹⁴,¹⁹]tricosane

C20H33N3 (315.2674)


   

(1s,7r,9r,10s)-1-[(2r)-piperidin-2-yl]-3,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadec-2-ene

(1s,7r,9r,10s)-1-[(2r)-piperidin-2-yl]-3,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadec-2-ene

C20H33N3 (315.2674)


   

1-[(1s,3as,3bs,7r,9ar,9bs,11ar)-7-amino-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

1-[(1s,3as,3bs,7r,9ar,9bs,11ar)-7-amino-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C21H33NO (315.2562)


   

(1s,2s,9r,10s)-1-[(2s)-piperidin-2-yl]-3,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadec-7-ene

(1s,2s,9r,10s)-1-[(2s)-piperidin-2-yl]-3,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadec-7-ene

C20H33N3 (315.2674)


   

(1s,2s,9s,10r)-1-[(2r)-piperidin-2-yl]-3,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadec-7-ene

(1s,2s,9s,10r)-1-[(2r)-piperidin-2-yl]-3,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadec-7-ene

C20H33N3 (315.2674)


   

3-[(1s,2s)-2-heptylcyclopropyl]-n-(2-phenylethyl)propanimidic acid

3-[(1s,2s)-2-heptylcyclopropyl]-n-(2-phenylethyl)propanimidic acid

C21H33NO (315.2562)


   

3-[(1r,2r)-2-heptylcyclopropyl]-n-(2-phenylethyl)propanimidic acid

3-[(1r,2r)-2-heptylcyclopropyl]-n-(2-phenylethyl)propanimidic acid

C21H33NO (315.2562)


   

(1r,2s,6r,11s,13r,14r,21r)-7,19,23-triazahexacyclo[9.9.1.1¹,¹³.1²,⁶.0⁷,²¹.0¹⁴,¹⁹]tricosane

(1r,2s,6r,11s,13r,14r,21r)-7,19,23-triazahexacyclo[9.9.1.1¹,¹³.1²,⁶.0⁷,²¹.0¹⁴,¹⁹]tricosane

C20H33N3 (315.2674)